Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxidized recombinant human galectin-1 is a modified form of the protein galectin-1 produced via recombinant DNA technology. Galectin-1 is a member of the beta-galactoside-binding lectin family and plays key roles in cell-cell and cell-matrix interactions, immune regulation, apoptosis, and tissue repair. In its oxidized state—characterized by the formation of disulfide bonds between cysteine residues—galectin-1 loses its carbohydrate-binding (lectin) activity but gains new biological functions. Notably, oxidized recombinant human galectin-1 has been shown to promote axonal regeneration and enhance functional recovery after peripheral nerve injury in animal models. It increases both the number and diameter of regenerating myelinated fibers at sites distal to nerve transection[1][4][9]. The protein’s redox-dependent switch alters its structure and function; while reduced forms bind carbohydrates on cell surfaces to modulate immune responses or tumor progression[2], oxidation leads to loss of lectin activity but acquisition of neuroregenerative properties[5]. Recombinant production typically uses E. coli expression systems for research purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxidized recombinant human galectin-1.